Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06980207 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

Name: A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 — clinical trial record (NCT06980207)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorLuye Pharma Group Ltd.

Started2025-05

View on ClinicalTrials.gov ↗

Record status

This record was last updated May 20, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Luye Pharma Group Ltd.

16 trials monitored

See all monitored trials

Parkinson's Disease

1,423 trials monitored

See 59 trials at risk

Alzheimer's Disease

1,140 trials monitored

See 62 trials at risk

Schizophrenia

675 trials monitored

See 32 trials at risk

This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects

Trial Details

NCT Number	NCT06980207
Lead Sponsor	Luye Pharma Group Ltd.
Conditions	Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
Enrollment	40 participants
Start Date	2025-05
Primary Completion	2025-10 (estimated)
Study Completion	2025-10 (estimated)
Updated on ClinicalTrials.gov	2025-05-20